CMV
FDA Grants New Indication for Orencia for Acute Graft-Versus-Host Disease Prophylaxis
Acute GvHD affects up to 70% of patients who receive an HCT, particularly those coming from unrelated and ...
DECEMBER 17, 2021
FDA Approves Livtencity for Post-Transplant Recipients With Refractory CMV
The FDA approved maribavir (Livtencity, Takeda) as the first drug for treating patients 12 years of age and older ...
NOVEMBER 24, 2021
CMV in Transplant Patients: Risk Factors, Therapeutic Strategies and New Directions
Cytomegalovirus can remain latent for long periods in a person with a healthy immune system, but can be reactivated ...
DECEMBER 26, 2019
CMV Reactivation and Rx After Allo-HCT Pose Substantial Toll
Reactivation of CMV infection and preemptive therapy to prevent progression to CMV disease in allo-HCT recipients ...
MARCH 21, 2018
Letermovir Prophylaxis Lowers CMV Risk in HCT Patients
The recently approved antiviral drug letermovir lowered the risk for clinically significant cytomegalovirus ...
FEBRUARY 23, 2018
FDA Approves Prevymis for CMV Prevention in Allo-HCT Patients
The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...
NOVEMBER 13, 2017
